dc.creator | Argüelles Arias, Federico | es |
dc.creator | Bermejo, Fernando | es |
dc.creator | Borrás-Blasco, Joaquín | es |
dc.creator | Domènech, Eugeni | es |
dc.creator | Sicilia, Beatriz | es |
dc.creator | Huguet, José M. | es |
dc.creator | Ramírez de Arellano, Antonio | es |
dc.creator | Valentine, William J. | es |
dc.creator | Hunt, Barnaby | es |
dc.date.accessioned | 2022-12-05T15:13:27Z | |
dc.date.available | 2022-12-05T15:13:27Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Argüelles Arias, F., Bermejo, F., Borrás-Blasco, J., Domènech, E., Sicilia, B., Huguet, J.M.,...,Hunt, B. (2022). Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. Therapeutic Advances in Gastroenterology, 15, 167-12. https://doi.org/10.1177/17562848221086131. | |
dc.identifier.issn | 1756-283X | es |
dc.identifier.issn | 1756-2848 | es |
dc.identifier.uri | https://hdl.handle.net/11441/140175 | |
dc.description.abstract | Background: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel
disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is
treated with iron supplementation, commonly with intravenous iron formulations, such as
ferric carboxymaltose (FCM), and iron sucrose (IS).
Methods: This study assessed the cost-effectiveness of FCM compared with IS, in terms of
additional cost per additional responder in patients with IDA subsequent to IBD in the Spanish
setting. An economic model was developed to assess the additional cost per additional
responder, defined as normalization or an increase of ⩾2g/dl in hemoglobin levels, for FCM
versus IS from a Spanish healthcare payer perspective. Efficacy inputs were taken from a
randomized controlled trial comparing the two interventions (FERGIcor). Costs of treatment
were calculated in 2021 Euros (EUR) using a microcosting approach and included the costs
of intravenous iron, healthcare professional time, and consumables. Cost-effectiveness was
assessed over one cycle of treatment, with a series of sensitivity analyses performed to test
the robustness of the results.
Results: FCM was more effective than IS, with 84% of patients achieving a response compared
with 76%. When expressed as number needed to treat, 13 patients would need to switch
treatment from IS to FCM in order to achieve one additional responder. Costs of treatment
were EUR 323 with FCM compared with EUR 470 with IS, a cost saving of EUR 147 with FCM.
Cost savings with FCM were driven by the reduced number of infusions required, resulting in a
reduced requirement for healthcare professional time and use of consumables compared with
the IS arm.
Conclusion: The present analysis suggests that FCM is less costly and more effective than IS
for the treatment of IDA subsequent to IBD in Spain and therefore was considered dominant. | es |
dc.format | application/pdf | es |
dc.format.extent | 12 p. | es |
dc.language.iso | eng | es |
dc.publisher | Sage Publishing | es |
dc.relation.ispartof | Therapeutic Advances in Gastroenterology, 15, 167-12. | |
dc.rights | Atribución-NoComercial 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | Cost | es |
dc.subject | Cost-effectiveness | es |
dc.subject | Inflammatory bowel disease | es |
dc.subject | Iron deficiency anemia | es |
dc.title | Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://journals.sagepub.com/doi/10.1177/17562848221086131 | es |
dc.identifier.doi | 10.1177/17562848221086131 | es |
dc.journaltitle | Therapeutic Advances in Gastroenterology | es |
dc.publication.volumen | 15 | es |
dc.publication.initialPage | 167 | es |
dc.publication.endPage | 12 | es |